Moderna, Inc. (MRNA) Discusses Phase III Data for Intismeran and Advances in Cancer Immunotherapy Transcript
Seeking Alpha · 2026-10-24
STOCKS · PHARMA
MRNA · Moderna
Latest news, signals, and AI analysis for Moderna (MRNA) on Catalayer. Updated continuously as stories are indexed across our news feed.
Recent MRNA News
Moderna: Why Positive Phase 3 Results Weren't Enough
Seeking Alpha · 2026-10-24
The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
MarketWatch Top · 2026-10-23
Doctors call Moderna, Merck cancer vaccine data a major advancement — despite Wall Street reaction
CNBC Top · 2026-10-23
Moderna: Data Leak Brings Us No Closer To Truth About Cancer Vaccine
Seeking Alpha · 2026-10-23
Merck/Moderna's Melanoma Combination Therapy Delivers Promising Phase 3 Trial Results
Seeking Alpha · 2026-10-23
Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares - Bloomberg.com
Bloomberg.com · 2026-10-23
Oncologists Cheer Melanoma Data That Tanked Moderna’s Shares - Bloomberg.com
Bloomberg.com · 2026-10-23
Stocks making the biggest moves premarket: AT&T, SpaceX, Moderna, Deckers, Bloom Energy and more
CNBC Top · 2026-10-23
Tempus AI: Moderna's New Cancer Vaccine Partner Is The Pick Of The AI Biotech Bunch
Seeking Alpha · 2026-10-23
Wall Street Breakfast Podcast: Moderna's Good News Goes Bad
Seeking Alpha · 2026-10-23
Moderna and Merck say their mRNA cancer vaccine cut death, recurrence by 42%
Ars Technica · 2026-10-22
Merck/Moderna cancer vaccine cuts melanoma death or recurrence risk by 42%, shares fall
Investing.com · 2026-10-22
Moderna shares sink after leaked cancer data missed expectations - Financial Times
Financial Times · 2026-10-22
Moderna, Merck Fall After Melanoma Data Leak
Bloomberg Markets · 2026-10-22
Moderna sheds about $24 billion as cancer vaccine data triggers 'sell-the-news' retreat - Reuters
Reuters · 2026-10-22
Moderna sinks 24% after doubts about its melanoma vaccine leak - Demócrata
Demócrata · 2026-10-22
Merck/Moderna cancer vaccine cuts risk of death or recurrence from melanoma by over 40% - Reuters
Reuters · 2026-10-22
Moderna shares plunge after leak of partial cancer vaccine data
CNBC Top · 2026-10-22
Moderna’s stock tumbles after reported leak of data for cancer vaccine
MarketWatch Top · 2026-10-22
Moderna shares plunge on apparent cancer vaccine data leak
Investing.com · 2026-10-22
Moderna, Merck Shares Fall After Possible Melanoma Data Leak - Bloomberg.com
Bloomberg.com · 2026-10-22
Moderna is about to release the trial results for its cancer vaccine. A lot is riding on this data.
MarketWatch Top · 2026-10-21
Related Tickers
$JNJ · Johnson & Johnson$LLY · Eli Lilly$PFE · Pfizer$MRK · Merck$ABBV · AbbVie$NVO · Novo NordiskFrequently Asked Questions
What sector does MRNA belong to?
MRNA (Moderna) is classified under the Pharma sector on Catalayer. You can browse all news in this sector at /sector/pharma.
Where can I track real-time MRNA news?
Catalayer aggregates MRNA coverage from Reuters, Bloomberg, CNBC, MarketWatch, Yahoo Finance, Seeking Alpha, Barron’s, WSJ, Motley Fool, Benzinga, TipRanks and 20+ other sources. View the live feed at https://catalayer.com/stocks/MRNA.
How fast are MRNA news alerts on Catalayer?
News is polled every 30–60 seconds. MRNA-related stories appear in your workspace within minutes of publication, and you can create a custom monitor to get instant alerts.
Does Catalayer provide AI analysis for MRNA?
Yes. The Market Intelligence tier adds AI-powered event classification (monetary policy, earnings, guidance, M&A), directional impact (bullish/bearish), magnitude, and affected-sector analysis to every MRNA story.
Is MRNA covered in any Catalayer signal channels?
Signal channels and custom keyword monitors both support MRNA. Free accounts get 1 monitor; Plus ($29/mo) unlocks 5 monitors with boolean rules across tickers, sectors, and topics.
Track MRNA in real time
Set up a monitor to get alerted when new news hits.